Investigational heart drug for nonobstructive HCM one step closer to FDA approval

June 25, 2026 - 20:17

An experimental oral medication for a specific type of hypertrophic cardiomyopathy is advancing toward potential U.S. approval. The drug, known as ninerafaxstat, is being developed for patients with symptomatic nonobstructive hypertrophic cardiomyopathy, or HCM. Currently, no therapies are specifically approved by the FDA for this form of the disease.

The U.S. Food and Drug Administration has granted the drug a Breakthrough Therapy designation, a status meant to speed up the development and review of treatments for serious conditions. This designation came after positive results from a mid-stage clinical trial. In that study, patients taking ninerafaxstat showed improvements in exercise capacity and symptoms compared to those on a placebo.

Nonobstructive HCM is a heart muscle disorder where the wall of the heart becomes thickened, but unlike the obstructive form, the blood flow out of the heart is not blocked. Patients often suffer from fatigue, shortness of breath, and chest pain, with limited treatment options beyond managing symptoms. Ninerafaxstat works by targeting energy metabolism in the heart, aiming to make the muscle more efficient.

The company developing the drug is now planning a larger Phase 3 trial, which is the final step before seeking full FDA approval. If successful, ninerafaxstat could become the first approved oral therapy specifically for this patient population, offering a new option for those who currently have none.